title: Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?
abstract: BACKGROUND
  Human epidermal growth factor receptor-2 (HER2) overexpression occurs in ∼20% of breast cancers and has historically been associated with decreased survival. Despite substantial improvements in clinical outcomes, particularly with the emergence of HER2-targeted therapy, a substantial minority of patients still relapses, and progression is inevitable in metastatic disease. Accumulating data indicate that HER2-positive disease is itself a heterogeneous entity.
  
  
  RESULTS
  In this article, we qualitatively review the data supporting the classification of HER2-positive disease as at least two separate entities, distinguished by estrogen receptor (ER) status. We summarize differences in clinical outcomes, including response to neoadjuvant therapy, timing and patterns of dissemination, efficacy of therapy in the metastatic setting and survival outcomes.
  
  
  CONCLUSIONS
  The collective data are sufficiently strong at this point to propose that ER status defines two distinct subtypes within HER2-positive breast cancer, and we highlight the implications of this knowledge in future research, including understanding of the basic biology of HER2-positive breast cancer and the design of future clinical trials.
authors.affiliation: Department of Medical Oncology, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA; Clinical and Translational Oncology Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal.
authors.forename: I
authors.initials: I
authors.lastname: Vaz-Luis
authors.affiliation: Department of Medical Oncology, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA.
authors.forename: E P
authors.initials: EP
authors.lastname: Winer
authors.affiliation: Department of Medical Oncology, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA. Electronic address: nancy_lin@dfci.harvard.edu.
authors.forename: N U
authors.initials: NU
authors.lastname: Lin
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics; D001943:Breast Neoplasms / Q000145:classification* / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D006801:Humans; D000077341:Lapatinib; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local; D011799:Quinazolines / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011944:Receptors, Androgen / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D000077341:Lapatinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D011944:Receptors, Androgen; D011960:Receptors, Estrogen; C508053:ERBB2 protein, human; C485206:pertuzumab